Olaparib: new treatment option for ovarian cancer

Olaparib (Lynparza) is an inhibitor of human poly (ADP-ribose) polymerase enzymes (PARP-1, PARP-2 and PARP-3).

In Europe, ovarian cancer is the fifth most commonly diagnosed cancer in women and the sixth leading cause of cancer death among women. | iStock
In Europe, ovarian cancer is the fifth most commonly diagnosed cancer in women and the sixth leading cause of cancer death among women. | iStock
Lynparza is indicated as monotherapy for patients with relapsed BRCA-mutated high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to platinum-based chemotherapy.

Pharmacology

Olaparib blocks repair of single-strand DNA breaks by binding to the active site of DNA-associated PARP, preventing the enzyme’s dissociation from the DNA. 

Clinical efficacy

Further information
View Lynparza drug record

Manufacturer: AstraZeneca

 was a randomised, double-blind, placebo-controlled phase II trial involving 265 patients with serous ovarian cancer, including fallopian tube or primary peritoneal cancer, who had been treated with at least two platinum-containing regimens. A total of 136 patients were assigned to the olaparib group and received 400mg twice daily; the other 129 received placebo.

Progression-free survival was significantly longer with olaparib than with placebo (median 8.4 months vs 4.8 months; hazard ratio for progression or death 0.35, 95% CI 0.25–0.49,  p<0.001). Patients taking olaparib had a lower risk of disease progression regardless of progression-free survival. 

In an interim analysis, overall survival did not differ significantly between patients taking olaparib and those taking placebo (p=0.75)

Adverse effects

Patients in the olaparib group experienced more side-effects than those in the placebo group, most commonly nausea (68%), fatigue (49%), vomiting (32%) and anaemia (17%). 

Eligibility

 does not recommend funding of Lynparza on the NHS. Treatment can be prescribed privately or for personally funded patients. 
 
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from intelog

New antibiotic guidance for diabetic foot infection

New antibiotic guidance for diabetic foot infection

NICE has updated its guidance on the prevention and...

Drug shortages - live tracker

Drug shortages - live tracker

Added: co-fluampicil.
Use our constantly updated...

Further drug shortages prompt advice to consider unlicensed alternatives

Further drug shortages prompt advice to consider unlicensed alternatives

Prescribers are being advised to prioritise supplies...

Vaping still safer than smoking, say health bosses after report of severe lung injury